NASDAQ$CGEM
Cullinan Oncology Inc · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Reported first quarter 2022 financial results and provided a corporate update.
Cullinan Oncology reported its Q1 2022 financial results, highlighting a cash position of $685 million, including an upfront payment from the Taiho collaboration, expected to provide runway through 2026. The company also made progress in advancing its pipeline, including CLN-081, CLN-049, and CLN-619.
- Announced a U.S. co-development and co-commercialization agreement for CLN-081 with Taiho Pharmaceutical.
- Updated CLN-081 data was accepted for oral presentation at the ASCO meeting in June.
- Phase I dosing continues for CLN-049 and CLN-619, with initial clinical data expected by mid-2023.
- IND submissions for CLN-081 and CLN-978 are on track for 1H 2023.
Headline financials
Revenue & EPS history
Cullinan Oncology · Revenue · Quarterly
$0
Forward guidance
Cullinan Oncology anticipates continued advancement of its pipeline programs and expects to file INDs for CLN-617 and CLN-978 in the first half of next year. The company's cash runway is expected to extend through 2026.
Tailwinds
- Advancing lead asset, CLN-081, and continuing to progress diversified pipeline.
- Sharing additional clinical update in an oral presentation at the upcoming ASCO meeting.
- Proceeds from the Taiho transaction will allow acceleration and expansion of the development of diverse pipeline.
- On track to file INDs for two additional programs, CLN-617 and CLN-978, in the first half of next year.
- Stronger financial position to continue advancing strategically built pipeline of diversified assets.
Headwinds
- Uncertainty regarding the timing and results of regulatory submissions.
- Success of clinical trials and preclinical studies is not guaranteed.
- Risks related to ability to protect and maintain intellectual property position.
- Risks related to manufacturing, supply, and distribution of product candidates.
- The risk that results of preclinical studies or clinical studies will not be predictive of future results in connection with future studies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-2.1%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+13.5%
Q1 2022
Best reaction
-10.8%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | +7.7% | -10.0% | |
| Q3 2025 | +0.8% | +6.7% | +44.9% | |
| Q2 2025 | -10.8% | -7.7% | -11.3% | |
| Q1 2025 | +2.3% | +1.3% | +5.8% | |
| Q4 2024 | +1.9% | -3.8% | -5.1% | |
| Q3 2024 | -2.8% | -2.8% | -20.8% | |
| Q1 2024 | -9.7% | -9.1% | -28.4% | |
| Q4 2023 | -6.2% | -8.7% | -1.8% | |
| Q3 2023 | -2.7% | -11.1% | -17.7% | |
| Q2 2023 | +4.3% | -1.4% | -0.6% | |
| Q1 2023 | +1.2% | -5.3% | +36.0% | |
| Q4 2022 | -1.5% | +3.3% | -9.1% | |
| Q3 2022 | +3.8% | +1.0% | -3.0% | |
| Q2 2022 | -5.6% | +0.8% | -3.5% | |
| Q1 2022 | +13.5% | +6.8% | +12.1% | |
| Q4 2021 | +8.8% | +3.0% | -8.6% | |
| Q3 2021 | -4.5% | -10.1% | -28.8% | |
| Q2 2021 | +7.8% | +3.8% | +8.0% | |
| Q1 2021 | +2.2% | +12.4% | +13.1% | |
| Q4 2020 | +9.5% | +8.4% | -13.9% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro